<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04970368</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-21-GYN-210</org_study_id>
    <nct_id>NCT04970368</nct_id>
  </id_info>
  <brief_title>Comparison of Nodal Staging in Endometrial Cancer</brief_title>
  <official_title>Randomized Phase 3 Study of Selective Versus Sentinel Node Surgical Staging for the Treatment of Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Frederick R. Ueland, M.D.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to estimate the recurrence-free survival rates in women with endometrial&#xD;
      cancer treated with selective versus sentinel node surgical staging.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2021</start_date>
  <completion_date type="Anticipated">September 2026</completion_date>
  <primary_completion_date type="Anticipated">September 2026</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>Recurrence-free survival rate in women with endometrial cancer treated with selective versus sentinel node surgical staging</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>Progress-free survival rate in women with endometrial cancer treated with selective versus sentinel node surgical staging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-specific survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>Disease-specific survival rate in women with endometrial cancer treated with selective versus sentinel node surgical staging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall patient survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>Overall survival rate in women with endometrial cancer treated with selective versus sentinel node surgical staging</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance of SELECTIVE and SENTINEL NODE surgical staging with final pathology</measure>
    <time_frame>5 years</time_frame>
    <description>Percentage of participants for whom selective surgical staging and final pathology match. Match incorporates grade, lesion size, depth of invasion, and low-risk (no lymphadenectomy) versus high-risk (lymphadenectomy).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient morbidity</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient mortality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Location patterns of nodal involvement associated with staging procedures</measure>
    <time_frame>5 years</time_frame>
    <description>Location patterns related to nodal involvement with staging procedures will be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of metastatic lymph node(s) associated with staging procedures</measure>
    <time_frame>5 years</time_frame>
    <description>The number of metastatic lymph node(s) associated with the staging procedures will be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patterns of nodal involvement associated with primary tumor grade</measure>
    <time_frame>5 years</time_frame>
    <description>Primary tumor grade related to nodal involvement will be reported</description>
  </other_outcome>
  <other_outcome>
    <measure>Patterns of nodal involvement associated with primary tumor lesion size</measure>
    <time_frame>5 years</time_frame>
    <description>Primary tumor lesion size related to nodal involvement will be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patterns of nodal involvement associated with primary tumor depth of invasion</measure>
    <time_frame>5 years</time_frame>
    <description>Primary tumor depth related to nodal involvement will be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Patterns of nodal involvement associated with primary tumor cell type</measure>
    <time_frame>5 years</time_frame>
    <description>Primary tumor cell type related to nodal involvement will be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Location patterns of nodal involvement associated with disease stage</measure>
    <time_frame>5 years</time_frame>
    <description>Location related to nodal involvement with disease stage will be reported.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of metastatic lymph node(s) associated with disease stage</measure>
    <time_frame>5 years</time_frame>
    <description>The number of metastatic lymph node(s) associated with the staging procedures will be reported.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Sentinel Node Surgical Staging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Selective Surgical Staging</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Sentinel node procedure</intervention_name>
    <description>Excision of ALL mapped nodes and other suspicious nodes regardless of mapping and label by anatomic location</description>
    <arm_group_label>Sentinel Node Surgical Staging</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Selective staging</intervention_name>
    <description>Intraoperative consultation (IOC)</description>
    <arm_group_label>Selective Surgical Staging</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Surgical candidate for complete hysterectomy and bilateral salpingooophorectomy with&#xD;
             pelvic and aortic lymphadenectomy&#xD;
&#xD;
          -  Histologically or cytologically confirmed endometrioid-type endometrial cancer&#xD;
             confined to the uterine corpus&#xD;
&#xD;
          -  No clinical evidence of extra-uterine disease on pre-operative evaluation.&#xD;
&#xD;
          -  Prior systemic chemotherapy is allowed so long as it was at least five years prior to&#xD;
             study enrollment, and there is no evidence of disease after such therapy.&#xD;
&#xD;
          -  Age â‰¥18 years.&#xD;
&#xD;
          -  Life expectancy (estimated survival) of at least 6 months.&#xD;
&#xD;
          -  AST(SGOT)/ALT(SGPT) &lt; 3.0X upper limit of normal&#xD;
&#xD;
          -  Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  GOG/ECOG Performance Status greater than 2&#xD;
&#xD;
          -  Non-endometrioid cell type&#xD;
&#xD;
          -  Clinical evidence of disease that extends beyond the uterus, including the presence of&#xD;
             suspicious aortic or inguinal nodes on imaging or clinical exam&#xD;
&#xD;
          -  Previous vaginal, pelvic or abdominal irradiation&#xD;
&#xD;
          -  Chemotherapy, hormone therapy or immunotherapy directed at the present disease&#xD;
&#xD;
          -  Previous pelvic lymphadenectomy or retroperitoneal surgery&#xD;
&#xD;
          -  Patients with a prior or concurrent malignancy whose natural history or treatment has&#xD;
             the potential to interfere with the safety or efficacy assessment of the&#xD;
             investigational regimen&#xD;
&#xD;
          -  Known allergy to iodine or indigocyanine green (ICG) tracer, or allergic reactions to&#xD;
             compounds of similar chemical or biologic composition&#xD;
&#xD;
          -  Patients with uncontrolled intercurrent illness&#xD;
&#xD;
          -  Patients with psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          -  Pregnant or lactating women&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederick Ueland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Frederick Ueland, MD</last_name>
    <phone>857-257-1613</phone>
    <email>fuela0@uky.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40506</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Frederick Ueland, MD</last_name>
      <phone>859-257-1613</phone>
      <email>fuela0@uky.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 25, 2021</study_first_submitted>
  <study_first_submitted_qc>July 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2021</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Frederick R. Ueland, M.D.</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Sentinel node</keyword>
  <keyword>Cancer</keyword>
  <keyword>Endometrial</keyword>
  <keyword>Intraoperative Consultation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

